Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India
This real-world data from LMIC confirm the safety and efficacy of alectinib in the first-line setting matching that of registration studies with similar safety and tolerance, without any new alarm.
Authors
- Anuradha Majumdar (ORCID: https://orcid.org/0000-0001-5314-7223)
- Trupti Pai (ORCID: https://orcid.org/0000-0001-5160-3897)
- Amit Janu (ORCID: https://orcid.org/0000-0002-4557-3553)
- Sima Baburao Manmode (ORCID: https://orcid.org/0000-0001-9187-2936)
- Vanita Noronha (ORCID: https://orcid.org/0000-0002-0191-2744)
- Akhil Kapoor (ORCID: https://orcid.org/0000-0001-6006-2631)
- Nandini Menon
- Nilendu Purandare (ORCID: https://orcid.org/0000-0003-0952-0347)
- Ahmad Ubharay (ORCID: https://orcid.org/0009-0003-6297-2809)
- Ajay Singh (ORCID: https://orcid.org/0000-0003-4969-7681)
- Rajiv Kumar (ORCID: https://orcid.org/0000-0003-0363-3287)
- Kumar Prabhash
- Vijay Patil
- Mehak Trikha
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
- Bombay College of Pharmacy (IN)
Publication Details
- Journal
- South Asian Journal of Cancer
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1055/s-0045-1806811
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00